L2D opens London and Lyon offices to expand European presence
The new London office, located at the city’s Bioscience innovation centre, is designed to provide pharma and biotech companies in the London, Oxford and Cambridge with access to L2D’s range of development services.
The Lyon unit, meanwhile, will target companies in the Rhone-Alps region, which L2D founder and director Jonathan Kearsey said was an extremely fast growing centre for pharmaceutical and biotech innovation.
Kearsey told Outsourcing-Pharma, “There is dynamism within the biotech sector of both of these regions, and we want to be physically close to it and to become a central player in the non-clinical development of the emerging therapeutics.”
L2D provides non-clinical drug development activities necessary to manage a therapeutic program, including preclinical development planning, pharmacology, GMP manufacturing, toxicology, ADME, pharmakinetics, and clinical trial application.
Assistance in clinical trial applications
In addition to this, L2D provides strategic and business services such as drug positioning and due diligence for biotechs, pharma companies, and investors.
Kearsey explained that biotech companies are finding it increasing difficult to develop multiple therapeutic programs simultaneously, as it is no longer financially viable to pay for a full time internal development team who function at just 30-40 per cent capacity.
Outsourcing these activities is a means of combating such a problem, said Kearsey, who believes that enlisting the help of a scientific project management company, such as L2D, has become “a very viable option” for reducing both the cost and time to reach the all important clinical milestones.
L2D are able to do this “thorough professional project management and performing the maximum number of tasks in parallel,” he said, adding that “No biotech company would initiate a clinical study today without the support of a clinical CRO.”
